Camilla Petrycer Hansen

Camilla Petrycer Hansen serves as Director on the Board of Directors for Precirix, LimmaTech Biologics AG, Centauri Therapeutics Limited, and Hoba Therapeutics, while holding the position of Observer on the Board of Directors for Muna Therapeutics and Hemab. Camilla is also a Principal at Novo Holdings within Novo Seeds and REPAIR, where prior roles included Senior Associate. Previous experience includes serving as Senior Manager for Business Development at Novozymes and Business Development Manager at Statens Serum Institut. Educational qualifications include a PhD in Medicinal Chemistry and a Cand. pharm. in Pharmaceutical Sciences, both from the University of Copenhagen.